Biopharmaceutical CMO and CRO

Biopharmaceutical CMO and CRO Market is Set to Grow to $59.4 Billion by 2030 Biopharmaceutical CMO and CRO Market - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 - 2030

Share This Article

As per the experts, the Biopharmaceutical CMO and CRO market is predicted to record a growth rate of 7.4% from 2021-2030 and is projected to reach US$ 59.4 billion by 2030.

The study provides the overall revenue of the global Biopharmaceutical CMO and CRO market from 2017 to 2030, considering 2020 as the base year and 2030 as the forecast year.

The global Biopharmaceutical CMO and CRO market research report gives a brief summary of definitions, size analysis, and place of production, sales, applications, types, and major players/key vendors of the Biopharmaceutical CMO and CRO industry. The report presents fresh perspectives on opportunities and challenges in a significantly transformed post-COVID-19 marketplace. This research study also integrates Industry Chain analysis and Porter’s Five Forces Analysis. Further, this report offers a competitive scenario that comprises collaborations, market concentration rate and expansions, mergers & acquisitions undertaken by companies.

Crucial factors accountable for market growth are:

  • Rapidly growing biopharmaceutical industry
  • Rising demand for the biopharmaceutical products
  • Increased participation of medium and small-sized enterprises in biologics
  • Growing government expenditure on building sophisticated healthcare infrastructure
  • Increasing adoption of biopharma drugs and therapeutics
  • Rising burden of diseases amongst the population
  • Presence of numerous CMOs and CROs in the market

We customize your report according to your research need. REQUEST SAMPLE OR CUSTOMIZED COPY OF THIS REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1289

Report Highlights

  • By service, the contract manufacturing segment led the global biopharmaceutical CMO and CRO market with remarkable revenue share in 2020. This is attributed to the growing participation of the small and medium conventional pharmaceutical developers in the biopharmaceutical industry owing to its market attractiveness.
  • By source, the mammalian segment led the global biopharmaceutical CMO and CRO market with remarkable revenue share in 2020. This is attributed to the growing importance of biotherapies namely, monoclonal antibodies, vaccines, and blood factors are developed using mammalian cell culture. Moreover, the antibody products are the dominant commercial products that foster the segment growth.
  • By product type, the biologics segment led the global biopharmaceutical CMO and CRO market with remarkable revenue share in 2020. Biologics gained traction when it opened up the opportunities for the treatment of cancer. Moreover, higher approval rate of biologic medicines is fostering its adoption at a rapid pace among the consumers.

Report Scope of the Biopharmaceutical CMO and CRO Market

Report Coverage Details
Market Size USD 59.4 Billion by 2030
Growth Rate CAGR of 7.4% From 2021 to 2030
Base Year 2020
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Product, Source, Service
Regional Scope North America, APAC, Europe, Latin America, MEAN, Rest of the World
Companies Mentioned Samsung Biologics, Lonza, BoehringerIngelheim, Patheon, CMC Biologics, TOYOBO Co. Ltd., JRS Pharma, RentschlerBiotechnologie, FUJIFILM Diosynth Biotechnologies, WuXi Biologics, PRA Health Sciences, LabCorp

Regional Snapshots

North America is the leading biopharmaceutical CMO and CRO market. The US accounts for around 33.33% of the global biopharmaceutical CMO market and is also the leader in biopharmaceutical CRO market. As per the Pharmaceutical Research and Manufacturers Association, US has the property rights on majority of the new medicines. North America is characterized by supportive setting for the commercialization and development of medicines, rewards to the developers in the form of intellectual property rights, and supportive regulatory framework for the biopharmaceuticals. This helps in attracting capital investments in North America region for the development of biopharmaceutical companies. This is a significant growth factor that boosts the growth and development of the biopharmaceutical CMO and CRO market in the region.

Asia Pacific is estimated to be the fastest-growing region, owing to enhanced regulatory framework regarding the biopharmaceuticals, greater supply of capital, and support from the government. In South Korea, the Samsung Biologics witnessed a spike in its sales by 56% in 2017. Further, the Celltrion Group of South Korea acquired European Medicines Agency approval for it biosimilar product called Herzuma, in 2018. Further, in India, Biocon received FDA approval for its biosimilar product called Ogivri in 2017. China, the second largest market for the biopharmaceuticals is attracting FDIs for setting up manufacturing units that exponentially propels the biopharmaceutical CMO and CRO market growth in Asia Pacific region.

Top Players Contending in the Market:

The key companies are aiming towards advanced innovations and are predictable to dominate the target market. Foremost players inspiring in the global Biopharmaceutical CMO and CRO market are as follows:

 

  • Lonza
  • JRS Pharma
  • Samsung Biologics
  • CMC Biologics
  • TOYOBO Co. Ltd.
  • RentschlerBiotechnologie
  • FUJIFILM Diosynth Biotechnologies
  • WuXi Biologics
  • Patheon
  • BoehringerIngelheim
  • PRA Health Sciences
  • LabCorp

Segments Covered in the Report

By Service

  • Contract Manufacturing
    • Process Development
      • Upstream
      • Downstream
    • Fill & Finish Operations
    • Analytical & QC studies
    • Packaging
  • Contract Research
    • Inflammation & Immunology
    • Cardiology
    • Oncology
    • Neuroscience
    • Others

By Source

  • Mammalian
  • Non-Mammalian

By Product

  • Biologics
    • Vaccines
    • Monoclonal antibodies (MABs)
    • Recombinant Proteins
    • Antisense, RNAi, & Molecular Therapy
    • Others
  • Biosimilars

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Rest of the World

Some of the key highlights of the report are:

  • Market Demand Outlook – The report offers refined forecasts on potential growth prospects for the market. Based on data derived after thorough research by a team of expert analysis, Precedence Research presents the most precise rate of growth for the market for the assessment period starting from 2021 – 2030.
  • Supply Chain Analysis – The purpose of the survey is to help companies identify potential scope for supply chain expansion. The study also presents analysis of unprecedented threats.
  • Competitive Landscape Analysis – Some of the leading companies operating in the Biopharmaceutical CMO and CRO market are profiled in the market study. The report also underscores winning strategies adopted over the last few years and gauges impact of the same on growth trajectory exhibited by the market over the last few years.

Why should you invest in this report?

If you are aiming to enter the global Biopharmaceutical CMO and CRO market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for Biopharmaceutical CMO and CRO are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Source Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Biopharmaceutical CMO and CRO Market, By Product

7.1. Biopharmaceutical CMO and CRO Market, by Product Type, 2021-2030

7.1.1. Biologics (Vaccines, Monoclonal antibodies (MABs), Recombinant Proteins, Others)

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. Biosimilars

7.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Biopharmaceutical CMO and CRO Market, By Service

8.1. Biopharmaceutical CMO and CRO Market, by Service, 2021-2030

8.1.1. Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC studies, Packaging)

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Contract Research (Inflammation & Immunology, Cardiology, Oncology, Neuroscience, Others)

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Biopharmaceutical CMO and CRO Market, By Source 

9.1. Biopharmaceutical CMO and CRO Market, by Source, 2021-2030

9.1.1. Mammalian

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Non-Mammalian

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Biopharmaceutical CMO and CRO Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Product (2017-2030)

10.1.2. Market Revenue and Forecast, by Service (2017-2030)

10.1.3. Market Revenue and Forecast, by Source (2017-2030)

10.1.4. U.S.

10.1.4.1. Market Revenue and Forecast, by Product (2017-2030)

10.1.4.2. Market Revenue and Forecast, by Service (2017-2030)

10.1.4.3. Market Revenue and Forecast, by Source (2017-2030)

10.1.5. Rest of North America

10.1.5.1. Market Revenue and Forecast, by Product (2017-2030)

10.1.5.2. Market Revenue and Forecast, by Service (2017-2030)

10.1.5.3. Market Revenue and Forecast, by Source (2017-2030)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Product (2017-2030)

10.2.2. Market Revenue and Forecast, by Service (2017-2030)

10.2.3. Market Revenue and Forecast, by Source (2017-2030)

10.2.4. UK

10.2.4.1. Market Revenue and Forecast, by Product (2017-2030)

10.2.4.2. Market Revenue and Forecast, by Service (2017-2030)

10.2.4.3. Market Revenue and Forecast, by Source (2017-2030)

10.2.5. Germany

10.2.5.1. Market Revenue and Forecast, by Product (2017-2030)

10.2.5.2. Market Revenue and Forecast, by Service (2017-2030)

10.2.5.3. Market Revenue and Forecast, by Source (2017-2030)

10.2.6. France

10.2.6.1. Market Revenue and Forecast, by Product (2017-2030)

10.2.6.2. Market Revenue and Forecast, by Service (2017-2030)

10.2.6.3. Market Revenue and Forecast, by Source (2017-2030)

10.2.7. Rest of Europe

10.2.7.1. Market Revenue and Forecast, by Product (2017-2030)

10.2.7.2. Market Revenue and Forecast, by Service (2017-2030)

10.2.7.3. Market Revenue and Forecast, by Source (2017-2030)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Product (2017-2030)

10.3.2. Market Revenue and Forecast, by Service (2017-2030)

10.3.3. Market Revenue and Forecast, by Source (2017-2030)

10.3.4. India

10.3.4.1. Market Revenue and Forecast, by Product (2017-2030)

10.3.4.2. Market Revenue and Forecast, by Service (2017-2030)

10.3.4.3. Market Revenue and Forecast, by Source (2017-2030)

10.3.5. China

10.3.5.1. Market Revenue and Forecast, by Product (2017-2030)

10.3.5.2. Market Revenue and Forecast, by Service (2017-2030)

10.3.5.3. Market Revenue and Forecast, by Source (2017-2030)

10.3.6. Japan

10.3.6.1. Market Revenue and Forecast, by Product (2017-2030)

10.3.6.2. Market Revenue and Forecast, by Service (2017-2030)

10.3.6.3. Market Revenue and Forecast, by Source (2017-2030)

10.3.7. Rest of APAC

10.3.7.1. Market Revenue and Forecast, by Product (2017-2030)

10.3.7.2. Market Revenue and Forecast, by Service (2017-2030)

10.3.7.3. Market Revenue and Forecast, by Source (2017-2030)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Product (2017-2030)

10.4.2. Market Revenue and Forecast, by Service (2017-2030)

10.4.3. Market Revenue and Forecast, by Source (2017-2030)

10.4.4. GCC

10.4.4.1. Market Revenue and Forecast, by Product (2017-2030)

10.4.4.2. Market Revenue and Forecast, by Service (2017-2030)

10.4.4.3. Market Revenue and Forecast, by Source (2017-2030)

10.4.5. North Africa

10.4.5.1. Market Revenue and Forecast, by Product (2017-2030)

10.4.5.2. Market Revenue and Forecast, by Service (2017-2030)

10.4.5.3. Market Revenue and Forecast, by Source (2017-2030)

10.4.6. South Africa

10.4.6.1. Market Revenue and Forecast, by Product (2017-2030)

10.4.6.2. Market Revenue and Forecast, by Service (2017-2030)

10.4.6.3. Market Revenue and Forecast, by Source (2017-2030)

10.4.7. Rest of MEA

10.4.7.1. Market Revenue and Forecast, by Product (2017-2030)

10.4.7.2. Market Revenue and Forecast, by Service (2017-2030)

10.4.7.3. Market Revenue and Forecast, by Source (2017-2030)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Product (2017-2030)

10.5.2. Market Revenue and Forecast, by Service (2017-2030)

10.5.3. Market Revenue and Forecast, by Source (2017-2030)

10.5.4. Brazil

10.5.4.1. Market Revenue and Forecast, by Product (2017-2030)

10.5.4.2. Market Revenue and Forecast, by Service (2017-2030)

10.5.4.3. Market Revenue and Forecast, by Source (2017-2030)

10.5.5. Rest of LATAM

10.5.5.1. Market Revenue and Forecast, by Product (2017-2030)

10.5.5.2. Market Revenue and Forecast, by Service (2017-2030)

10.5.5.3. Market Revenue and Forecast, by Source (2017-2030)

Chapter 11. Company Profiles

11.1. Lonza

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. JRS Pharma

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Samsung Biologics

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. CMC Biologics

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. TOYOBO Co. Ltd.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. RentschlerBiotechnologie

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. FUJIFILM Diosynth Biotechnologies

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. WuXi Biologics

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Patheon

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. BoehringerIngelheim

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

11.11. PRA Health Sciences

11.11.1. Company Overview

11.11.2. Product Offerings

11.11.3. Financial Performance

11.11.4. Recent Initiatives

11.12. LabCorp

11.12.1. Company Overview

11.12.2. Product Offerings

11.12.3. Financial Performance

11.12.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase This Premium Research Report @ https://www.precedenceresearch.com/checkout/1289

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semiconductors, chemicals, automotive, and aerospace & defence, among different ventures, present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://precedenceresearchnews.wordpress.com

Follow us on LinkedIn | Twitter | Facebook

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

View all posts by Precedence Research →